MENU
LVTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
LAVA Therapeutics (LVTX) Ownership - Who owns LAVA Therapeutics?
LAVA Therapeutics NV isa clinical stage immuno-oncology company... Show more
Profile
Industry
N/A
Address
Yalelaan 62
Phone
+31 850163100
Employees
35
Web
https://www.lavatherapeutics.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
40.25M
P/E Ratio
N/A
Total Cash
66.56M
Projected Growth
N/A
Total Debt
312K
Revenue
4.99M
Risk (Beta)
0.59
Dividend Yield
N/A
Total Cash/Share
2.53
Total Debt/Equity
N/A
Revenue/Share
0.19 USD as % of share price
Fundamentals
LVTX
Capitalization
40.2M
P/E Ratio
N/A
Risk (Beta)
0.59
Dividend Yield
N/A
Total Cash
66.6M
Total Cash/Share
2.53
Total Debt
312K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.19%
Revenue
4.99M
ROE
N/A
Book Value
25.8M
P/B Ratio
1.56
Cash Flow
N/A
Earnings
-1.05
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
3.72M
Current Ratio
6.73
Current Revenue Per Employee
188972.97
Dividends Per Share - Security
N/A
EBITDA
-26.26M
Float
N/A
Float - Current
N/A
Gross Income Margin
100.00
Revenue To Assets
-32.88
Shares Held By Institutions
10.3M
Shares Outstanding - Current
26.3M
Total Liabilities
45.4M
Total Volume MTD
N/A
Value
1
Gain YTD
60.883
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. LVTX showed earnings on May 14, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
Yalelaan 62
Phone
+31 850163100
Employees
35
Web
https://www.lavatherapeutics.com